Registry for safety and effectiveness of alopecia areata treatments
Official title: CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Run by CorEvitas · NCT05745389 · Data updated 2026-11-12
This study is trying to collect information from about 5,000 people with alopecia areata to see how safe and effective different treatments are over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | CorEvitas Research network |
| Locations | 1 site (Waltham, Massachusetts) |
| Status | Recruiting |
| Started | October 25, 2022 |
| Main results expected | December 31, 2099 |
| Study ends | December 31, 2099 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT05745389 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry are adults aged 18 and older who have been diagnosed with alopecia areata by a qualified dermatologist and are starting a prescribed treatment.
✕Probably not a fit
Patients currently participating in a double-blind randomized trial for an alopecia areata drug will not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort registry aims to recruit approximately 5,000 subjects diagnosed with alopecia areata under dermatological care across 100 clinical sites in North America. The primary objective is to gather long-term data on the safety and effectiveness of various treatments for alopecia areata, addressing the limited understanding of these factors post-regulatory approval. By collecting structured data, including patient-reported and clinician-reported outcomes, the registry will help characterize the disease's natural history and inform clinical decision-making. Additionally, it will allow for linkages to other databases for comprehensive evaluation of treatment impacts.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the long-term safety and effectiveness of alopecia areata treatments, ultimately improving patient care.
How similar studies have gone: Other observational studies have successfully gathered long-term data on treatment safety and effectiveness, making this approach both relevant and valuable.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A subject must meet all the following criteria to participate in the registry: 1. Has been diagnosed with alopecia areata by a dermatologist or a qualified dermatology practitioner. 2. Is at least 18 years of age or older. 3. Is willing to provide Personal Information. 4. Is prescribed or starting an Enrollment Eligible Medication at the time of enrollment. Exclusion Criteria: * Any of the following would exclude the subject from participating in the registry: 1. Is participating or planning to participate in a double-blind randomized trial for an AA drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.
Where it's running
-
CorEvitas, LLC
Waltham, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Cathy Cheney
- Email: corevitasregistrytrials@corevitas.com
- Phone: (508) 408-5435
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?
This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.
-
Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata
This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.
-
VC005 tablets in teens with severe alopecia areata
This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.
-
VC005 tablets in severe alopecia areata
This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.
-
Ritlecitinib for patchy hair loss in teens and adults with alopecia areata
This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.
-
Alopecia Areata: looking at ferroptosis markers in blood
This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.